Allergy Therapeutics plc (LON:AGY)‘s stock had its “buy” rating restated by equities research analysts at FinnCap in a research note issued to investors on Friday. They presently have a GBX 47 ($0.62) price objective on the stock. FinnCap’s price target points to a potential upside of 26.17% from the company’s previous close.

Other research analysts have also issued research reports about the company. Panmure Gordon reissued a “buy” rating on shares of Allergy Therapeutics plc in a report on Thursday, September 28th. Numis Securities Ltd reissued a “buy” rating and set a GBX 45 ($0.60) price objective on shares of Allergy Therapeutics plc in a report on Thursday, September 28th.

Shares of Allergy Therapeutics plc (LON AGY) opened at 37.25 on Friday. The stock’s market cap is GBX 221.31 million. Allergy Therapeutics plc has a 12-month low of GBX 19.50 and a 12-month high of GBX 39.50. The stock’s 50 day moving average is GBX 33.25 and its 200-day moving average is GBX 29.03.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at

In other Allergy Therapeutics plc news, insider Tunde Otulana bought 25,000 shares of the stock in a transaction on Wednesday, October 11th. The shares were purchased at an average price of GBX 51 ($0.68) per share, with a total value of £12,750 ($16,941.27).

About Allergy Therapeutics plc

Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company’s segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World.

Receive News & Stock Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related stocks with our FREE daily email newsletter.